Big Board

Keyword
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Purnanand Sarma-Led Immunome Announces Initial Public Offering Pricing
2 IPO Launch: Immunome Prepares For $30 Million IPO
3 Immunome to become Philadelphia region's sixth life sciences IPO of 2020
4 Immunome Announces Creation of COVID-19 Advisory Board
5 Immunome Appoints Purnanand Sarma, PhD, as President and Chief Executive Officer
6 Form 3 Immunome Inc. For: Oct 01 Filed by: Lefenfeld Michael
7 Immunome Appoints Purnanand Sarma as President and CEO
8 Chester County immunotherapy company names new CEO
9 Immunome to get up to $13.3M in government funding for potential Covid-19 drug
10 Vaxess Technologies Closes Final Tranche of $8.2 Million Series A and Appoints Dr. Purnanand Sarma to the Board
11 Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19
12 TARIS CEO Purnanand Sarma Says $25 Million Series B Funding Will Focus on Bladder Cancer and Overactive Bladder Programs
13 pH Pharma and Immunome Enter into Collaboration and License Agreement to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates in Oncology
14 TiE Boston Recognizes Entrepreneurs at 2019 Gala: Lifetime Achievement Award for Indian American edX CEO Anant Agarwal
15 Ph Pharma and Immunome to collaborate in antibody-drug conjugates
16 TARIS Biomedical® Announces $25M Series B Financing
17 TARIS Announces Positive Topline Data for TAR-302 in Patients with Idiopathic Overactive Bladder
18 Vaxess Technologies Closes Funding for Administering Vaccines Through a Bandage
19 TARIS Appoints Tony Kingsley as President and Chief Executive Officer
20 TiE Boston to Honor edX CEO Anant Agrawal With Lifetime Achievement Award, Present Entrepreneurship Awards in 10 Categories
21 FDA grants fast track designation to Gem-RIS for muscle-invasive bladder cancer
22 Taris launches another Phase I trial for bladder cancer drug-device combo
23 TARIS Biomedical® Announces Positive Results from Ph1b Trial of TAR-200 (GemRISTM) in Patients with Muscle Invasive Bladder Cancer
24 TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer
25 Allergan Acquires LiRIS® Program from TARIS Biomedical®
26 US, Canada and Australia raise objections at WTO over Indian ban on import of pulses
27 Vaxess Technologies Closes Final Tranche of $8.2M Series A Funding
28 Taris 2.0: A Year After Buyout, VCs Bet $32M More on a Second Strike
29 Should You Bet On Transdermal Drug Delivery?
30 A New Device For A Chronic Bladder Problem
31 TAR-200, Opdivo Combo Tested for Muscle Invasive Bladder Cancer
32 TARIS™ Initiates Phase 2 Clinical Study with LiRIS in Interstitial Cystitis Patients | Small Molecules | News Channels
33 These Device Startups Are Challenging the Status Quo
34 Rupal Ramesh Shah Talks About Lessons Learned From Competing in Six World Marathon Majors
35 Rare Disease Day 2020
36 Taris reboots with $32m round for bladder tech